Barry, OppHub America Desk · · Source: prnewswire-all
Akeso's ADC AK158D1 Gains China Phase I Clearance
Akeso is advancing its pipeline, aiming to address limitations of current treatments. Investors monitoring the oncology space may watch for further clinical data on AK158D1 and other candidates in Akeso's portfolio.
Based on reporting from prnewswire-all.
Akeso, Inc. (9926.HK) announced its investigational bispecific antibody-drug conjugate AK158D1 targeting EGFR and TROP2 has received Phase I clinical trial clearance from China's NMPA. This marks Akeso's fourth clinical-stage ADC candidate, advancing its immuno-oncology strategy.
Market context for this story
As of: After HoursLoading quotes…
Informational only — not investment advice. Full markets →
$ADC
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/ADC and related $CDE. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Akeso, Inc. (9926.HK) announced on September 17, 2026, that AK158D1, its bispecific antibody-drug conjugate ($ADC+WL) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from China's National Medical Products Administration (NMPA). The trial will evaluate the candidate in patients with advanced malignant solid tumors.
AK158D1 represents Akeso's fourth $ADC+WL to enter clinical development and is part of its strategy to combine next-generation immuno-oncology approaches with $ADC+WL platforms. The company aims to address limitations of single-target ADCs, such as narrow tumor coverage and toxicity, by integrating dual targeting with a potent cytotoxic payload and an enhanced safety profile. Preclinical data have shown potent anti-tumor activity with a favorable safety profile.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Akeso is advancing its pipeline, aiming to address limitations of curren
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 17, 2026 at 3:02 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
oncology biotech
A biotech company got permission to start human safety tests for a new cancer-fighting drug that targets two different proteins at once. Investors care because successful early tests can drive up the value of companies working on advanced cancer treatments.
What changed
Akeso secured NMPA Phase I clinical trial clearance in China for its bispecific antibody-drug conjugate AK158D1.
Who wins / who loses
Oncology pipeline developers benefit from validation in bispecific ADCs, while single-target drug competitors face pressure to innovate.
Time horizon
Think in terms of the next few months.
Confidence & best fit
low confidence · Long-term investor
Low confidence → prefer ETFs and “Watch,” not rushing into one stock.
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $HKWatch — track, don’t rush
This is the company making the new cancer drug, and investors are watching to see if its early tests go well.
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here entirely because early-stage drug trials are unpredictable and risky.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor global competitor pipelines working on EGFR and TROP2 bispecific ADCs.
What would break this thesis
- Clinical holds or unfavorable safety data from early trials of AK158D1.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-all.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).